SEC 13F Intelligence

Managers / Q1 2023 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$116M
Q1 2023
Positions
31
Filings on Record
16
2019–present window
Filed
Apr 14, 2023
original filing

Summary

Bml Capital Management, LLC reported $116M in U.S.-listed holdings across 31 positions for Q1 2023.

Its largest position, BIL, represents 15.9% of the portfolio.

Compared with Q4 2022, the fund opened 12 new positions and exited 6.

Portfolio Metrics

Turnover
+37.5%
vs prior filed quarter
Top-10 Concentration
+67.6%
share of reported value
Largest Position
+15.9%
Spdr
New / Exited
12 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 48.5%ETP: 26.7%Other: 24.7%
  • Common Stock · 48.5% · $56M
  • ETP · 26.7% · $31M
  • Other · 24.7% · $29M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SGOVISHARES TRNEW+125.0K125.0K+$13M$13M
CYTEIR THERAPEUTICS INCNEW+3.15M3.15M+$6M$6M
ELVNENLIVEN THERAPEUTICS INCNEW+212.2K212.2K+$5M$5M
TALARIS THERAPEUTICS INCNEW+1.93M1.93M+$4M$4M
EMBARK TECHNOLOGY INCNEW+1.29M1.29M+$4M$4M
ORMPORAMED PHARMACEUTICALS INCNEW+1.36M1.36M+$3M$3M
JOUNCE THERAPEUTICS INCNEW+1.09M1.09M+$2M$2M
CARMCARISMA THERAPEUTICS INCNEW+411.4K411.4K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2023

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BILSPDR SER TRhistory →BLOOMBERG 1-3 MO15.87%$18M200.0K
2SGOVISHARES TRhistory →0-3 MNTH TREASRY10.87%$13M125.0K
3TILLYS INCCL A7.70%$9M1.15M
4ANFABERCROMBIE & FITCH COhistory →CL A7.09%$8M295.8K
5CYTEIR THERAPEUTICS INCCOM4.95%$6M3.15M
6PARDES BIOSCIENCES INCCOM4.55%$5M3.99M
7ADVERUM BIOTECHNOLOGIES INCCOM4.38%$5M7.07M
8CLYMELIEM THERAPEUTICS INChistory →COM4.16%$5M1.66M
9ATHIRA PHARMA INCCOM4.03%$5M1.86M
10ELVNENLIVEN THERAPEUTICS INChistory →COM4.02%$5M212.2K
11SATSUMA PHARMACEUTICALS INCCOM3.89%$4M6.44M
12IRONDISC MEDICINE INChistory →COM3.81%$4M208.2K
13TALARIS THERAPEUTICS INCCOM3.14%$4M1.93M
14EMBARK TECHNOLOGY INCCOM NEW3.12%$4M1.29M
15METACRINE INCCOM3.04%$4M6.17M
16ORMPORAMED PHARMACEUTICALS INChistory →COM NEW2.56%$3M1.36M
17ASTCASTROTECH CORPhistory →COM2.03%$2M220.4K
18JOUNCE THERAPEUTICS INCCOM1.74%$2M1.09M
19FORTE BIOSCIENCES INCCOM1.51%$2M1.74M
20ARCA BIOPHARMA INCCOM1.22%$1M706.9K
21CARMCARISMA THERAPEUTICS INChistory →COM1.10%$1M411.4K
22RVPRETRACTABLE TECHNOLOGIES INChistory →COM1.01%$1M668.6K
23VERRICA PHARMACEUTICALS INCCOM0.84%$975,000150.0K
24SURROZEN INCCOM0.78%$899,4101.49M
25MISTMILESTONE PHARMACEUTICALS INCOM0.75%$866,800220.0K
26LSTALISATA THERAPEUTICS INCCOM0.68%$791,258243.8K
27NEXTCURE INCCOM0.39%$453,568306.5K
28GRPHGRAPHITE BIO INCCOM0.32%$373,113152.3K
29PASSAGE BIO INCCOM0.28%$323,192337.5K
30ADICET BIO INCCOM0.15%$172,80030.0K
31NEOLEUKIN THERAPEUTICS INCCOM0.01%$16,62423.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.